Form 4: Rocket Pharma Officer Sells Shares Under 10b5-1 Plan

Rocket Pharmaceuticals' VP of Finance, John Militello, sold 1,086 shares of common stock on November 18, 2025, at $2.983 per share, as part of a pre-arranged 10b5-1 plan.

Summary

• John Militello, Vice President of Finance, Treasurer, and Principal Accounting Officer of Rocket Pharmaceuticals, Inc. (RCKT), filed a Form 4 reporting a transaction.
• The filing details the disposition of 1,086 shares of common stock.
• The transaction occurred on November 18, 2025.
• The shares were sold at a price of $2.983 per share.
• Following this transaction, Militello beneficially owns 65,920 shares of common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, which provides an affirmative defense against insider trading allegations.
• Holdings include Restricted Stock Units (RSUs) that convert to common stock on a one-for-one basis.

Sentiment

Score: 5

Explanation: The insider sale is a neutral event due to its execution under a Rule 10b5-1 plan, which indicates a pre-scheduled transaction rather than one based on new, non-public information. While it reduces insider ownership, the pre-planned nature mitigates negative sentiment.

Positives

• The transaction was executed under a Rule 10b5-1(c) plan, indicating it was pre-scheduled and not based on new, non-public information, which enhances transparency and mitigates concerns about opportunistic insider selling.

Negatives

• The sale by a key executive, even if pre-scheduled, reduces insider ownership and could be perceived as a minor negative signal regarding future stock performance or management's conviction.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This insider transaction is a routine disclosure for publicly traded companies and does not inherently reflect broader industry trends or competitive dynamics.

Related Party Transactions

• The disposition of common stock by John Militello, an officer of Rocket Pharmaceuticals, Inc., constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view the reduction in insider ownership as a minor negative, though the execution under a 10b5-1 plan mitigates concerns about opportunistic selling, suggesting minimal impact.

Key Dates

Recommendation

The Form 4 filing reports a routine, pre-planned stock sale by an executive under a Rule 10b5-1 plan. This type of transaction is generally not indicative of new material information and does not warrant a change in investment recommendation based solely on this filing. Investors should continue to monitor the company's fundamental performance and broader market conditions.

Keywords

ROCKET PHARMACEUTICALS, RCKT, John Militello, insider transaction, Form 4, stock sale, 10b5-1 plan, officer, equity disposition